LIXTE Biotechnology Sees 40% Disease Control Rate in Ovarian Cancer Trial
Preliminary results from 20 evaluable patients in a combination trial of LB-100 and dostarlimab showed a 40% disease control rate and encouraging survival trends with an acceptable safety profile. These data support enrolling an expanded cohort to evaluate the regimen’s potential in enhancing immunotherapy response for ovarian clear cell carcinoma.
1. Interim Ovarian Cancer Trial Results
LIXTE Biotechnology presented preliminary data from a clinical trial combining its proprietary PP2A inhibitor LB-100 with dostarlimab in ovarian clear cell carcinoma, reporting a 40% disease control rate among 20 evaluable patients alongside encouraging survival trends and an acceptable safety profile.
2. Trial Expansion and Pipeline Focus
Based on these interim outcomes, LIXTE will enroll an expanded patient cohort to further assess the combination’s efficacy, while its broader pipeline includes proof-of-concept trials in metastatic colon cancer and advanced soft tissue sarcoma.
3. LB-100 Mechanism and Technology Platforms
LB-100, a first-in-class clinical PP2A inhibitor, is designed to enhance chemotherapies and immunotherapies through activation lethality and is supported by a comprehensive patent portfolio. Through its subsidiary Liora Technologies, the company is also developing electronically controlled proton therapy systems.